



Chronic Obstructive Pulmonary Disease (COPD)

A VA Clinician's Guide

VA



U.S. Department of Veterans Affairs

Veterans Health Administration
PBM Academic Detailing Services

Chronic Obstructive Pulmonary Disease (COPD)

A VA Clinician's Guide

VA



U.S. Department of Veterans Affairs

Veterans Health Administration
PBM Academic Detailing Services

Contents

Background.....	1
Initial assessment and diagnosis.....	1
Developing a treatment plan for COPD	2
Appendix	17
References	19
Abbreviations.....	21



This document aims to provide clarity in selecting optimal goals and evidence-based treatments for chronic obstructive pulmonary disease.

These materials were developed by:

**VA Pharmacy Benefits
Management Academic
Detailing Services**

Key Messages

<i>Evaluate all patients with clinical indicators for COPD and diagnose with spirometry.....</i>	<i>2</i>
<i>Encourage smoking cessation regardless of COPD severity.....</i>	<i>4</i>
<i>Vaccinate all Veterans with COPD with influenza vaccine annually and pneumococcal vaccine as recommended.</i>	<i>5</i>
<i>Use a LAMA as initial therapy for patients with persistent symptoms.....</i>	<i>7</i>
<i>Use LAMA + LABA for patients with continued symptoms or exacerbations on LAMA monotherapy.</i>	<i>9</i>
<i>Add ICS to LAMA + LABA therapy when symptoms persist, or Veteran has an exacerbation on LAMA + LABA therapy.....</i>	<i>10</i>

Background

Did you know?

Almost 16 million Americans have been diagnosed with chronic obstructive pulmonary disease (COPD). The actual prevalence is likely much higher since many people with low pulmonary function are unaware of their condition and remain undiagnosed.¹⁻³ COPD was the 6th leading cause of death in the United States in 2020 and the 2nd most common cause of admission for an ambulatory care sensitive condition from 2022-2023.^{4,5}

COPD has historically been a disease of men, however, more recently in North America the prevalence in women has surpassed men (8.1% women vs 7.3% men).⁶ Prevalence of COPD is highest in rural areas with 8.2% of people in rural areas having COPD compared to 4.7% in large metro areas.¹ The goal in treating COPD is to improve symptoms and reduce acute exacerbations. An acute COPD exacerbation occurs when a patient has increased dyspnea and/or cough and sputum that worsens in less than 14 days. The risk of death increases as the number and severity of exacerbations increase.

Initial assessment and diagnosis

COPD should be considered in patients with any clinical indicators for COPD.⁸ Airway obstruction is the hallmark of COPD. Spirometry is used to confirm the diagnosis of COPD.

Table 1.
Clinical indicators of COPD⁸⁻¹¹

Clinical Indicators	
Dyspnea	Progressive over time; worsens with exertion; persistent
Chronic cough	Intermittent or persistent; productive or unproductive
Recurrent wheezing	
Recurrent lower respiratory tract Infections	
History of risk factors	Use or exposure to tobacco smoke; smoke from heating or cooking; occupational vapors, fumes, gases, dusts, etc.; host factors*

*Genetic factors, developmental abnormalities, low birthweight, prematurity, childhood respiratory infections, etc.

Figure 1.
Use spirometry to confirm diagnosis of COPD⁸⁻¹¹

Spirometry Testing

- COPD is confirmed by a $FEV_1/FVC < 0.70$ (or below the Lower Limit of Normal (LLN))* , tested after bronchodilator
- If the Veteran does not have a record of pulmonary function tests (PFTs) being performed, order PFTs to confirm diagnosis of COPD

*Lower Limit Normal is based on age-appropriate cut-offs in post-bronchodilator spirometry.



Eliminating exposure to tobacco smoke and reducing air pollution exposure can prevent COPD in most individuals.^{6,8,11}

KEY MESSAGE Evaluate all patients with clinical indicators for COPD and diagnose with spirometry.

Developing a treatment plan for COPD

Simply prescribing an inhaler for a patient with COPD is not a treatment plan. Treatment decisions for COPD patients should be individualized, multi-modal, and guided by symptoms, symptom severity, comorbidities, and the frequency of acute exacerbations.^{8,11}

Note: *As part of the shared decision-making process, a patient's ability to use an inhaler device and their preference should be considered.*


Figure 2.
Elements of a COPD treatment plan^{8,11}

<p>Smoking Cessation</p>	<p>Quitting tobacco has the greatest impact on slowing COPD progression and improves mortality. (See Tobacco Use Disorder (sharepoint.com) for more information).</p>
<p>Vaccines</p>	<p>Influenza vaccination reduces COPD exacerbations and hospitalizations. Pneumococcal vaccinations reduce the rate of community-acquired pneumonia in patients with COPD. Routine vaccinations are recommended for patients with COPD as they are for the general population and include Zoster, tetanus/diphtheria/pertussis (Tdap), COVID-19, and respiratory syncytial virus (RSV).</p>
<p>Pharmacotherapy</p>	<p>Pharmacotherapy reduces symptoms, frequency, and severity of COPD exacerbations, and improves exercise tolerance and health status.</p>
<p>Non-Pharmacologic</p>	<p>Proper nutrition, exercise, and use of pulmonary rehabilitation therapies (if criteria are met) help improve quality of life and reduce exacerbations.</p>
<p>Treating Other Comorbidities</p>	<p>The most common cause of death in Veterans with COPD is cardiovascular disease. Addressing this, along with other common comorbidities, like depression, lung cancer, obesity, and osteoporosis, is vital to the overall health of patients with COPD.</p>

Smoking cessation

Ask every patient with COPD if they smoke tobacco. If they do, smoking cessation should be addressed. Smoking cessation improves survival in patients with COPD, including older patients.^{12,13} Veterans who say they are ready to quit in the next 30 days should receive pharmacotherapy support (e.g., nicotine replacement, bupropion, or varenicline).^{14,15}

Figure 3.
Pathway for addressing tobacco use – The 5 A's¹⁵⁻¹⁷



Behavioral supports with evidence for benefit include individual sessions, group sessions, or provider support via telephone or Quitline (the VA National Quitline is: 1-855-QUIT-VET (1-855-784-8838)). See the Academic Detailing Services (ADS) [Tobacco Use Disorder SharePoint Site \(intranet\)](#) for more detailed information on pharmacotherapy for tobacco cessation.

Note

Encourage a no smoking policy for home, car, and work settings to reduce exposure to secondhand smoke and prevent relapse.




KEY MESSAGE

Encourage smoking cessation regardless of COPD severity.

Vaccines

Annual influenza vaccination can significantly reduce the incidence of lower respiratory infections and death in people with COPD.^{8,18,19} Pneumococcal vaccination reduces the incidence of community-acquired pneumonia (CAP) and exacerbations in people with COPD.^{20,21}

Figure 4.
Vaccine timing for adults with COPD*8,20,21




*Recommended CDC Vaccination and Immunization schedule: www.cdc.gov/vaccines.

KEY MESSAGE Vaccinate all Veterans with COPD with influenza vaccine annually and pneumococcal vaccine as recommended.

Pharmacotherapy for stable (non-exacerbating) COPD

Pharmacotherapy can reduce symptoms, decrease the risk and severity of exacerbations, and improve health status and exercise tolerance.^{8,11,23–26} Long-acting bronchodilators used in patients with symptomatic COPD have been shown to decrease dyspnea, improve quality of life, and decrease exacerbations when compared to placebo.¹¹ Long-acting bronchodilators are preferred over short-acting agents for initial treatment in patients with persistent symptoms because they improve lung function, dyspnea, and health status as well as reduce exacerbations. Short-acting agents only improve dyspnea and temporarily improve lung function.^{8,27–30}

Figure 5.
Pharmacotherapy for COPD based on VA/DoD Guidelines¹¹



Management of Chronic Obstructive Pulmonary Disease (COPD) (2021) - VA/DoD Clinical Practice Guidelines

STEP 1


Initial treatment in most patients with persistent symptoms is starting with a long-acting muscarinic antagonist (LAMA). Evidence shows LAMA to reduce exacerbations and increase time to first exacerbation compared to long-acting beta agonists (LABA).^{11,27–32}

- Short-acting bronchodilators can be considered in patients with intermittent symptoms
 - Short-acting muscarinic antagonists (SAMA) and short-acting beta agonists (SABA) have comparable efficacy.


- SABA can be added to LAMA therapy in patients who need immediate relief, prescribed on an as-needed schedule. SAMA should not be used in patients on LAMA due to increased risk of anticholinergic side effects.

Figure 6.
Reduced annual rate of exacerbations and increased time to first exacerbation with tiotropium (LAMA) monotherapy compared to salmeterol (LABA)³¹

Tiotropium reduced annual rate of exacerbations by 11% and severe exacerbations by 27%



Tiotropium increased the time to first exacerbation by 42 days



POET-COPD trial comparing tiotropium to salmeterol in patients with moderate-to-very-severe COPD and a history of exacerbations in the previous year ($p < 0.05$ for all comparisons in figures).

KEY MESSAGE


Use a LAMA as initial therapy for patients with persistent symptoms.

STEP 2

If symptoms persist or if the Veteran experiences an exacerbation, add LABA.


- Combination of LAMA + LABA reduces COPD exacerbations and increases the time to first exacerbation compared to LABA + ICS.^{33,34}
- Assess adherence with therapy and inhaler technique.

Figure 7.
Mean change from baseline in trough FEV₁ at week 24 with umeclidinium + vilanterol (LAMA + LABA) compared to umeclidinium (LAMA) and salmeterol (LABA) monotherapies.³³



EMAX trial evaluating umeclidinium/vilanterol (LAMA + LABA), umeclidinium (LAMA) and salmeterol (LABA) for improving COPD stability in patients at low exacerbation risk not receiving inhaled corticosteroids. Primary endpoint was trough forced expiratory volume in 1 second (FEV₁) at Week 24.

Figure 8.
Combination of LAMA + LABA reduced COPD exacerbations and increased the time to first exacerbation compared to LABA + ICS³⁴



FLAME trial evaluating Glycopyrrrolate + indacaterol (LAMA + LABA) compared to salmeterol-fluticasone (LABA + ICS) in patients with COPD and a history of at least one exacerbation in the previous year. The trial was designed to evaluate the annual rate of all COPD exacerbations ($p < 0.001$ for all comparisons in figure).



KEY MESSAGE

Use LAMA + LABA for patients with continued symptoms or exacerbations on LAMA monotherapy.


STEP 3

If symptoms persist or if the Veteran experiences exacerbations, add inhaled corticosteroid (ICS).

- LAMA + LABA + ICS
 - Use LAMA + LABA and a separate ICS inhaler or LABA + ICS and a separate LAMA first line. If Veteran is unable to use multiple inhalers then consider triple therapy single LAMA + LABA + ICS inhaler.

Figure 9.


Rates of moderate or severe exacerbations were lower using LAMA + LABA + ICS compared to LAMA + LABA or LABA + ICS in patients with moderate to very severe COPD³⁵



ETHOS trial evaluated the use of annual rate of moderate or severe COPD exacerbations in patients taking triple therapy at two dose levels of ICS compared to LAMA + LABA and LABA + ICS. Both triple therapy regimens had lower rates of exacerbations. + LAMA + LABA + ICS low dose = glycopyrrolate formoterol + budesonide 160 µg; LAMA + LABA + ICS high dose = glycopyrrolate + formoterol + budesonide 320 µg LABA + ICS = formoterol + budesonide 320 µg; LAMA + LABA = glycopyrrolate + formoterol.

Figure 10.

Triple therapy versus dual therapy in patients with moderate to severe COPD³⁶



IMPACT trial evaluated the use of umeclidinium+vilanterol (LAMA + LABA), vilanterol + fluticasone furoate (LABA + ICS), and umeclidinium + vilanterol + fluticasone furoate (LAMA + LABA + ICS) in patients with moderate to severe COPD. LAMA + LABA + ICS had the lowest rate of exacerbations.

KEY MESSAGE Add ICS to LAMA + LABA therapy when symptoms persist, or Veteran has an exacerbation on LAMA + LABA therapy.

VA/DoD Clinical Practice Guidelines Management of Chronic Obstructive Pulmonary Disease compared to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report.

VA/DoD Clinical Practice Guidelines are based on a systematic review of both clinical and epidemiological evidence developed by multidisciplinary experts. On the other hand, GOLD reports are not guidelines with measures of strength of evidence or certainty of recommendations, nor are they specific to United States or Veteran populations. The VA/DoD guidelines are designed to provide information and assist in decision making but are not intended to define a standard of care.

Table 2.
Comparing VA/DoD Guidelines to the Global Initiative for COPD (GOLD) Report.

VA/DoD CPG 2021 ¹¹	GOLD Report 2024 ⁸
Step 1: LAMA tiotropium (Spiriva [®])	Group A: LAMA or LABA* mMRC 0–1 or CAT <10 and 0–1 moderate exacerbation**
Step 2: LAMA + LABA tiotropium + olodaterol (Stiolto [®])	Group B: LAMA + LABA mMRC ≥2 or CAT ≥10 and 0–1 moderate exacerbation**
Step 3: LAMA + LABA + ICS tiotropium + olodaterol (Stiolto [®]) + mometasone HFA (Asmanex [®])	Group E: LAMA + LABA Consider LAMA + LABA + ICS with history of asthma, blood eosinophils ≥300, or frequent and severe exacerbations Any score on mMRC or CAT and ≥2 moderate exacerbations or ≥1 leading to hospitalization

CAT = COPD Assessment Test; mMRC = Modified Medical Research Council Breathlessness Scale; See [Appendix A](#) for the full questionnaires. *LAMA or LABA for patients with persistent symptoms. SAMA or SABA can be used instead for Group A if only occasional dyspnea. **Not leading to hospitalization.

Use of inhaled corticosteroids

Monotherapy with ICS is not recommended in patients with COPD since it does not improve FEV₁ or decrease exacerbations.⁸ If the Veteran has COPD in addition to asthma and an ICS is indicated, a LAMA should be provided with or without LABA. Blood eosinophil counts (eos) may help predict response to ICS (eos >300 cells/μL (0.3 cells/nL) = greater likelihood to respond, eos <100 cells/μL (0.1 cells/nL) = lower likelihood to respond).^{8,36–41}

ICS inhalers have adverse effects which need to be considered and discussed before prescribing. ICS adverse effects include:^{8,42–44}

- Oral candidiasis
- Skin bruising
- Hoarse voice
- Pneumonia

Patients at highest risk of pneumonia related to ICS include patients:

- ✓ Who smoke
- ✓ Are >55 years of age
- ✓ Have a history of pneumonia
- ✓ Have a body mass index <25 kg/m²
- ✓ Have severe airflow limitation

Note


Withdrawal of inhaled corticosteroids

Corticosteroid inhalers may need to be discontinued. In some cases, corticosteroids can be discontinued without tapering. For some patients, tapering may be needed, particularly if they are using high dose ICS or have a history of exacerbations after discontinuing ICS.^{37–38} When tapering, the dose should be slowly tapered from high dose ICS to moderate dose ICS, to low dose ICS every 6 weeks to avoid worsening of symptoms. Caution should be used when withdrawing ICS in patients with blood eosinophils ≥ 300 cells/ μL (0.3 cells/nL) due to a higher risk of experiencing more exacerbations after stopping ICS.^{8,42–46}

Possible candidates for ICS discontinuation include patients with:⁸

- Pneumonia
- Inappropriate original indication for ICS
- No symptom improvement while taking ICS
- Stable COPD without exacerbation in the past 2 years¹¹
- Eosinophil count < 300 cells/ μL (0.3 cells/nL)

Goals of treatment for stable COPD^{8,11}



Follow up assessment and treatment of COPD


Follow up treatment is based on how the patient responded⁸

- If the patient had an adequate response to the initial treatment, then maintain it.
- If not, modify treatment as indicated.

Figure 11.

Proper inhaler technique is critical for effective COPD pharmacotherapy^{8,11}

- ✓ *Provide instructions and demonstrate proper technique when prescribing an inhaler device.*
- ✓ *Spacers may improve drug delivery when used with metered dose inhalers (MDI).*
- ✓ *Inhaler technique and adherence to therapy should be assessed before considering dose adjustments and/or changing therapy. (Links to VA Instructional Videos in the Veteran Health Library: [Combivent Respimat, Pressurized Metered Dose Inhaler, HandiHaler, Mometasone Twisthaler, How to Use a Nebulizer, Wixela Inhub Inhaler](#))*



When inhalers are not enough

In patients with continued exacerbations despite maximizing inhaler therapy, a referral to a pulmonologist is recommended. Roflumilast or azithromycin may be indicated.^{8,47-49}


Table 3.
Comparing roflumilast and macrolide antibiotic (azithromycin)

Roflumilast*	Macrolide antibiotic
Indicated for patients with FEV ₁ < 50% with ≥ 1 recorded exacerbation requiring systemic steroids, unscheduled healthcare contact, or hospitalization in the previous year.	Azithromycin is the macrolide of choice for this indication. Best evidence is for use in patients who are former smokers. May reduce exacerbation rates in some patients.
Patients should be on optimal bronchodilator therapy (LAMA + LAMA) +/- ICS. Prescribing should be done by a pulmonologist or designated expert.	Patients should be on optimal bronchodilator therapy (LAMA + LABA) +/- ICS. Prescribing should be done by a pulmonologist or designated expert.
Avoid use in patients with depression, may increase risk of suicide. Contraindicated in patients with moderate to severe liver impairment.	Associated with an increased incidence of bacterial resistance, prolongation of QTc interval, and impaired hearing tests.
Roflumilast 500 mg tablet orally once daily; may initiate at 250 mg daily for 4 weeks to reduce adverse effects.	Azithromycin 250 mg orally once daily or 500 mg three times weekly. No data showing benefit beyond one year of treatment. Patients should be re-assessed annually.

Criteria for use of roflumilast is available at <https://www.va.gov/formularyadvisor/>. See ADS COPD Quick Reference Guide for more detailed medication information.

Non-pharmacologic interventions

Non-pharmacologic interventions are an important part of the treatment plan for all patients with COPD.



Pulmonary rehabilitation

Pulmonary rehabilitation is an evidence-based, multidisciplinary intervention for patients with chronic respiratory disease who are symptomatic and have a reduction in daily life activities.^{8,11,52,53}

Pulmonary rehabilitation

- Reduces symptoms, optimizes functional status, increases participation in care, and reduces healthcare costs
- May benefit patients with moderate to severe COPD⁸
- Should be provided at diagnosis, at discharge after hospitalization for an exacerbation, or when symptoms are progressively deteriorating.⁸ Check with your local facility about the referral process for pulmonary rehabilitation.

Oxygen therapy

Using supplemental oxygen long-term (>15 hours a day) increases survival in patients with chronic respiratory failure and severe chronic resting hypoxemia.⁵⁴ Long-term oxygen does not prolong survival or time to first hospitalization or provide sustained benefit in health status, lung function, or 6-minute walk distance in patients with stable COPD and moderate resting or exercise-induced arterial desaturation.⁵⁵

Oxygen is indicated when oxygen saturation (SaO_2) falls below 88% to keep $\text{SaO}_2 > 90\%$ ^{8,11}

- PaO_2 at or below 55 mmHg (7.3 kPa) or $\text{SaO}_2 \leq 88\%$, or
- PaO_2 between 56 mmHg (7.3 kPa) and 59 mmHg (8.0 kPa), or SaO_2 of $> 88\%$ and $< 90\%$, with evidence of tissue hypoxia (hematocrit $> 55\%$, pulmonary hypertension, or cor pulmonale).

Recheck SaO_2 60 to 90 days after starting oxygen therapy to decide if:

- Supplemental oxygen is still indicated
- Prescribed supplemental oxygen is effective

See [VHA Directive 1173.13\(1\) Home Oxygen Program](#) for additional information. [Centers for Medicare and Medicaid Services](#) has information on coverage for home oxygen therapy.


?
Did You Know

Participation in the VA COPD CARE team-based service led by Clinical Pharmacist Practitioners (CPP) resulted in greater access to health care, increased receipt of COPD management best practices, and readmission reduction compared to treatment as usual.⁵⁶

Treating other comorbidities

Treating comorbidities is very important for optimal management of COPD.

Figure 12.
Conditions that are of greatest concern



Appendix A



Your name: _____

Today's date: _____

How is your COPD? Take the COPD Assessment Test™ (CAT)

This questionnaire will help you and your healthcare professional to measure the impact that COPD (Chronic Obstructive Pulmonary Disease) is having on your wellbeing and daily life. Your answers and test score can be used by you and your healthcare professional to help improve the management of your COPD and gain the greatest benefit from the treatment.

For each item below, place a mark (X) in the box that best describes your current situation. Please ensure that you only select one response for each question.

Example: I am very happy

0	1	2	3	4	5
---	---	---	---	---	---

 I am very sad

		SCORE						
I never cough	<table border="1"><tr><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr></table>	0	1	2	3	4	5	I cough all the time
0	1	2	3	4	5			
I have no phlegm (mucus) on my chest at all	<table border="1"><tr><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr></table>	0	1	2	3	4	5	My chest is full of phlegm (mucus)
0	1	2	3	4	5			
My chest does not feel tight at all	<table border="1"><tr><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr></table>	0	1	2	3	4	5	My chest feels very tight
0	1	2	3	4	5			
When I walk up a hill or a flight of stairs I am not out of breath	<table border="1"><tr><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr></table>	0	1	2	3	4	5	When I walk up a hill or a flight of stairs I am completely out of breath
0	1	2	3	4	5			
I am not limited to doing any activities at home	<table border="1"><tr><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr></table>	0	1	2	3	4	5	I am completely limited to doing all activities at home
0	1	2	3	4	5			
I am confident leaving my home despite my lung condition	<table border="1"><tr><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr></table>	0	1	2	3	4	5	I am not confident leaving my home at all because of my lung condition
0	1	2	3	4	5			
I sleep soundly	<table border="1"><tr><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr></table>	0	1	2	3	4	5	I do not sleep soundly because of my lung condition
0	1	2	3	4	5			
I have lots of energy	<table border="1"><tr><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td></tr></table>	0	1	2	3	4	5	I have no energy at all
0	1	2	3	4	5			

TOTAL SCORE

--	--

A COPD assessment test was developed by an interdisciplinary group of international COPD experts with support from GSK. GSK's activities in connection with the COPD assessment test are monitored by a supervisory council that includes external, independent experts, one of which is chair of the council. CAT, the COPD assessment test and the CAT logo are trademarks that belong to the GSK group of companies. ©2009 GSK. All rights reserved.

Appendix B

Table 1.
Modified medical research council breathlessness scale

Grade	Description of breathlessness
0	I only get breathless with strenuous exercise
1	I get short of breath when hurrying on level ground or walking up a slight hill
2	On level ground, I walk slower than people of the same age because of breathlessness, or have to stop for breath when walking at my own pace
3	I stop for breath after walking about 100 yards or after a few minutes on level ground
4	I am too breathless to leave the house or I am breathless when dressing

References

1. Croft JB, Wheaton AG, Liu Y, et al. Urban-Rural County and State Differences in Chronic Obstructive Pulmonary Disease — United States, 2015. *MMWR Morb Mortal Wkly Rep*. 2018; 67:205–211. DOI: <http://dx.doi.org/10.15585/mmwr.mm6707a1>.
2. Mannino DM, Homa DM, Akinbami LJ, Ford ES, and Redd SC. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease surveillance—United States, 1971–2000. *MMWR Surveill Summ*. 2002; 51: 1–16.
3. Hill K, Golstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. *CMAJ*. 2010; 182(7):673–8.
4. Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. *JAMA*. 2021;325(18):1829–1830. doi:10.1001/jama.2021.5469.
5. US Department of Veterans Affairs. 172VA10P2: VHA Corporate Data Warehouse – VA. 79 FR4377. Accessed May 16, 2019.
6. Criner GJ, Bourbeau M, Diekemper RL, et al. Prevention of Acute Exacerbations of COPD. American College of Chest Physicians and Canadian Thoracic Society Guidelines. *Chest*. 2015;147(4):894–942.
7. Connors, AF Jr, Dawson, NV, Thomas, C et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). *Am J Respir Crit Care Med*. 1996; 154: 959–967b.
8. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2024 Report. Global Initiative for Chronic Obstructive Lung Disease website. Accessed 2/1/2024. <https://goldcopd.org/2024-gold-report/>.
9. Siu AL, Bibbins-Domingo K, Grossman DC, et al. Screening for chronic obstructive pulmonary disease: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2016; 315(13):1372–7.
10. Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2007; 147(9):633–8.
11. U.S. Department of Veterans Affairs, Department of Defense. VA/DoD Clinical Practice Guidelines for the Management of Chronic Obstructive Pulmonary Disease. Veterans' Health Administration, Office of Quality, Safety and Value and Office of Evidence Based Practice. The Management of Chronic Obstructive Pulmonary Disease Working Group; April 2021.
12. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-Century hazards of smoking and benefits of cessation in the United States. *NEJM*. 2013; 368:341–350.
13. Centers for Disease Control and Prevention (US); National Center for Chronic Disease Prevention and Health Promotion (US); Office on Smoking and Health (US). How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2010. PMID: 21452462.
14. U.S. Preventative Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons. US Preventative Task Force Recommendation Statement. *JAMA*. 2021;325(3):265–279. doi:10.1001/jama.2020.25019.
15. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service. May 2008.
16. Barua RS, Rigotti NA, Benowitz NL, et al. 2018 ACC expert consensus decision pathway on tobacco cessation treatment. *J Am Coll Cardio*. 2018; 72:3332–65.
17. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress. A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014.
18. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. *Cochrane database of systematic reviews (Online)*. 2006(1):CD002733.
19. Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. *Chest*. 2004; 125(6):2011–20.
20. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. *Archives of internal medicine*. 1999; 159(20):2437–2442.
21. Walters JA, Tang JN, Poole P, et al. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2017;1: Cd001390.
22. Murthy N, Wodi AP, McNally V, Cineas S, Ault K. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2023. *MMWR Morb Mortal Wkly Rep* 2023;72:141–144. DOI: <http://dx.doi.org/10.15585/mmwr.mm7206a2>.
23. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J*. 2005; 26(2):319–38.
24. Pellegrino R, Viegi G, Brusasco V, et al. Interpretive strategies for lung function tests. *Eur Respir J*. 2005; 26(5):948–68.
25. Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. *Eur Respir J*. 2009; 34(3):648–54.
26. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Etiology of Chronic Bronchitis (MRC breathlessness score). *BMJ*. 1960; 2:1662.
27. Sestini P, Renzoni E, Robinson S, et al. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2002;(4):CD001495.
28. Kew KM, Mavergames C, Walters JA. Long-acting beta2 agonists for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2014;10(10):CD010177.
29. Appleton S, Poole P, Smith B, et al. Long-acting beta 2-agonists for poorly reversible chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2006; 3(3):CD001104.
30. Barr RG, Bourbeau J, Camargo CA, et al. Inhaled tiotropium for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2005;(2):CD002876.
31. Vogelmeir C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *NEJM*. 2011; 364(12):1093–1103.
32. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomized, blinded, parallel-group study. *The Lancet Respiratory Medicine*. 2013; 1(7):524–33.

References (cont.)

33. Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomized trial. *Respir Res* 2019; 20(1): 238.
34. Wedzicha J.A., Banerji D., Chapman K.R., et al: Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. *NEJM*. 2016; 374: pp. 2222–2234.
35. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate to very severe COPD. *N Engl J Med* 2020;383:35–48.
36. Lipson DA, Barnhart F, Brealey N, et al. Once daily single inhaler triple versus dual therapy in patients with COPD. *NEJM*. 2018; 378(18):1671–80.
37. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *NEJM*. 2014; 371:1285–94.
38. Chapman KR, Hurst JR, Frent SM, et al. Long-term triple therapy de-escalation to indacaterol/ glycopyrronium in COPD patients (SUNSET): a randomized, double-blind, triple-dummy clinical trial. *Am J Respir Crit Care Med*. 2018; 198(3):329–339.
39. Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. *European Respiratory Journal* 2018 52: 1801230; DOI: 10.1183/13993003.01230-201.
40. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood eosinophils: A biomarker of response to extra fine beclomethasone/formoterol in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2015; 192(4):523–5.
41. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomized trials. *The Lancet Respiratory Medicine*. 2018; 6(2):117–26.
42. Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. *Annals of the American Thoracic Society*. 2015; 12(1):27–34.
43. Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. *Respir Med*. 2017; 131:27–34.
44. Yang IA, Clarke MS, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2012; 7(7):CD002991.
45. Cataldo D, Derom E, Liistro G, et al. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice. *Int J Chron Obstruct Pulmon Dis*. 2018; 13:2089–2099. Published 2018 Jul 5. doi:10.2147/COPD.S164259.
46. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. *NEJM*. 2014; 371(14):1285–1294.
47. Martinez FJ, Rabe KF, Sethi S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting beta-2-agonist on chronic obstructive pulmonary disease exacerbations (RE2SPOND) A randomized clinical trial. *Am J Respir Crit Care Med*. 2016; 194(5):599–67.
48. Rabe KF, Calverley PMA, Martinz FJ, et al. Effect of roflumilast in patients with severe COPD and a history of hospitalization. *Eur Respir J*. 2017; 50(1) 1700158; DOI: 10.1183/13993003.
49. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. *NEJM*. 2011; 365(8):689–98. Ortega F, Toral J, Cejudo P, et al. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2002; 166(5):669–74.
50. Lahham A, McDonald CF, Holland AE. Exercise training alone or with the addition of activity counseling improves physical activity level in COPD: a systematic review and meta-analysis of randomized controlled trials. *Int J Chron Obstruct Pulmon Dis*. 2016; 11:31–21–36.
51. Ortega F, Toral J, Cejudo P, et al. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2002; 166(5):669–74.
52. Nici L, Donner C, Wouters E, et al. ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. *Am J Respir Crit Care Med*. 2006; 173:1390–1413.
53. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2015; 2(2): CD003793.
54. Cranston JM, Crockett AJ, Moss JR, et al. Domiciliary oxygen for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2005; (4): CD001744.
55. Long-term Oxygen Treatment Trial Research Group. A randomized trial of long-term oxygen for COPD with moderate desaturation. *NEJM*. 2016; 375(17):1617.
56. Portillo et al. Integration of the patient-centered medical home to deliver a care bundle for chronic obstructive disease. *JAPhA*: 63(2023)212-219.

Abbreviations

COPD: chronic obstructive pulmonary disease

EOS: eosinophils

FEV₁: forced expiratory volume in one second

FVC: forced vital capacity

GOLD: Global Initiative for Chronic Obstructive Lung Disease

IC: inspiratory capacity

ICS: inhaled corticosteroid

Kg: kilograms

kPa: kilopascal; a unit of pressure

LABA: long-acting beta-2 agonist

LAMA: long-acting muscarinic antagonist

LLN: lower limit of normal

m²: meters squared

mg: milligrams

mmHg: millimeters
of mercury

nL: nanoliter

PaO₂: partial pressure of oxygen in arterial blood

PFT: pulmonary function tests

QTc: corrected QT interval; represents the duration of ventricular depolarization and repolarization

RSV: respiratory syncytial virus

SABA: short-acting beta-2 agonist

SAMA: short-acting muscarinic antagonist

SaO₂: arterial oxygen saturation

Tdap: tetanus diphtheria pertussis

μL: microliter

Contributions

This summary was written by:

Julianne Himstreet,
Pharm D., BCPS

Daina L Wells, Pharm D.,
MBA, BCPS, BCPP

Sarah J. Popish,
Pharm D., BCPP

We thank our expert reviewers:

David Au, MD

Jennifer Bierach, MD

Lucas Donovan, MD

Lynn Hickox, Pharm.D

Bryan Jennings,
Pharm.D., BCACP

Chad Kay, Pharm.D., BCPS

Lynn Keenan, MD

Debbie
Khachikian, Pharm.D.

William Llamas, Pharm.D.

Leiha Lutz, Pharm.D.

Kimberly
Schnacky, Pharm.D.

Heather Tanner, Pharm.D.

Sarah Will, Pharm.D, BCPS

J. Michael Wells, MD, SMPH

W.C. Yarbrough, MD

U.S. Department of Veterans Affairs

This reference guide was created as a tool for VA providers and is available from the Academic Detailing Services SharePoint.

These are general recommendations only. The treating provider should make clinical decisions based on an individual patient's clinical condition.

VA PBM Academic Detailing Services Email Group
PharmacyAcademicDetailingProgram@va.gov

VA PBM Academic Detailing Services SharePoint Site
<https://dvagov.sharepoint.com/sites/vhaacademicdetailing/>

VA PBM Academic Detailing Services Public WebSite
<http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp>